

Eprosartan (mesylate)

Catalog No: tcsc2291



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

144143-96-4

Formula:

$C_{24}H_{28}N_2O_7S_2$

Pathway:

GPCR/G Protein

Target:

Angiotensin Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 48 mg/mL (92.20 mM)

Alternative Names:

SKF-108566J

Observed Molecular Weight:

520.62

Product Description


Eprosartan is a nonpeptide angiotensin II receptor antagonist with IC₅₀ of 9.2 and 3.9 nM in rat and human adrenal cortical membranes, respectively.

IC₅₀ Value: 9.2 nM(in rat adrenal cortical membranes); 3.9 nM(in human adrenal cortical membranes)

Target: Angiotensin Receptor Type-1(AT1)

in vitro: Eprosartan mesylate, is one of the highly selective, orally active, non-peptide angiotensin-II-receptor antagonists [1]. In rat and human adrenal cortical membranes, Eprosartan displaced specifically bound [¹²⁵I]All with IC₅₀ of 9.2 and 3.9 nM, respectively. Eprosartan also inhibited [¹²⁵I]All binding to human liver membranes (IC₅₀ = 1.7 nM) and to rat mesenteric artery membranes (IC₅₀ = 1.5 nM). In rabbit aortic smooth muscle cells, Eprosartan caused a concentration-dependent inhibition of All-induced increases in intracellular Ca⁺⁺ levels. In rabbit aortic rings [2].

in vivo: Administration of Eprosartan (3-10 mg/kg) intraduodenally or intragastrically to conscious normotensive rats resulted in a dose-dependent inhibition of the pressor response to All (250 ng/kg, i.v.). At 10 mg/kg, i.d., significant inhibition of the pressor response to All was observed for 3 hr. In this same rat model, Eprosartan had no effect on base-line pressure or on the pressor response to norepinephrine or vasopressin [2]. Eprosartan is highly effective and safe in lowering blood pressure, notably SBP, in older subjects with mild to moderate hypertension [3]. Treatment with eprosartan in once-daily doses up to 1200 mg alone or in combination with HCTZ was well tolerated, with dizziness and asthenia being the most common side effects [4]. Therapy with eprosartan mesilat was associated with significant hypotensive effect (more evident in patients with high systolic blood pressure), improvement in 24-hour blood pressure profile and quality of life, and lower probability of secondary stroke. Side effects were not observed [5].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!